Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy

Trial Profile

Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Amlodipine (Primary) ; Olmesartan medoxomil (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 05 Jun 2009 Results were published in Clinical Drug Investigation, Volume 29, Number 7, 5 June 2009.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top